RET rearrangements [36] and HER2 mutations [37] are associated with a low PD-L1 expression, while EGFR activating mutations [38], ALK rearrangements [39], ROS1 rearrangements [37] and MET exon 14 skipping mutations [40] relate with a high PD-L1 expression simultaneously decreasing tumor mutations burden and the level of tumor infiltrating lymphocytes (TILs) that result in limited response to ICIs [24,31]. This evidence concerns the gene ROS1 and neoplasm.